About

Katie L. Kaput was born and raised in a rural community in southern Michigan. She earned a bachelor's degree in Biology from The University of Georgia and was employed at the Complex Carbohydrate Research Center in Athens, Georgia before attending medical school. She received her medical degree at Michigan State College of Osteopathic Medicine in East Lansing, Michigan and later completed her residency at National Jewish Health with Saint Joseph Hospital in Denver, Colorado. She then completed Endocrinology Fellowship Training at the University of Utah in Salt Lake City, Utah. Her career goal is to provide high quality, personalized endocrine care with an emphasis on preventative health and management of chronic illnesses.

Research topics

• Medicine
• Internal medicine
• Pediatrics
• Surgery
• Biology
• Endocrinology

Selected publications

• Between the Guidelines: Variability in Management of Patients With Cystic Fibrosis and Dysglycemia

  Endocrine Practice · 2026-03-01

  articleOpen accessSenior author

  OBJECTIVES: Abnormalities in glucose metabolism detected by oral glucose tolerance test occur frequently in people with cystic fibrosis (CF) and can have clinical implications. Cystic fibrosis related diabetes (CFRD) guidelines don't address management of dysglycemia in people with CF without diabetes. METHODS: We developed a 34-question survey to query pre-CFRD management practices among US based endocrinologists. Respondents were current or former participants in the EnVision-CF Program. We analyzed responses quantitatively and qualitatively. Data are presented descriptively. RESULTS: The most common next step after abnormal oral glucose tolerance test was placing a continuous glucose monitor, though insurance coverage was a barrier to use. Despite the high rate of continuous glucose monitor use, the specific metrics deemed most important to providers varied. Endocrinologists cited multiple factors influencing their decision to treat pre-CFRD, including CF-specific and general diabetes goals. Most respondents reported at least sometimes considering use of medication in management of pre-CFRD. Common treatment options were basal insulin alone (75%) or bolus insulin alone (60%). Many also considered noninsulin medications including glucagon-like peptide-1 agonists and biguanides. CONCLUSIONS: This survey of US endocrinologists with CF expertise offers valuable insight into current practices for managing pre-CFRD, while highlighting considerable variation in clinical practice. Respondents agreed on key long-term outcomes as priorities for future care, but management differed regarding use and choice of diagnostic tools and medications. This study serves as an important indicator of the need for ongoing research to guide development of evidence-based guidelines in this area to better inform clinical practice.

  PublisherOA PDFDOI

• Aging With Cystic Fibrosis: Endocrine and Metabolic Considerations

  Endocrine Practice · 2026-02-01 · 1 citations

  article1st author
  PublisherDOI

• Evaluation of Family History of Diabetes and the Development of Cystic Fibrosis-Related Diabetes in a Clinical Cystic Fibrosis Cohort

  Endocrine Practice · 2026-04-01

  article1st authorCorresponding
  PublisherDOI

• 683 Practice habit variability among endocrinologists caring for patients with cystic fibrosis & dysglycemia

  Journal of Cystic Fibrosis · 2025-10-01

  articleSenior author
  PublisherDOI

• Patient and provider factors associated with follow-up for positive depression screens in adults: a retrospective review of University of Utah primary and specialty care clinics

  BMJ Open · 2025-01-01

  reviewOpen access

  OBJECTIVE: To identify patient and provider factors associated with lower rates of follow-up for positive depression screens in outpatient settings. DESIGN: Retrospective cohort study with electronic health record analysis investigating factors associated with follow-up care for patients with moderate-to-severe depressive symptoms. Patient and provider variables were associated with rates of follow-up for positive depression screens. SETTING: University of Utah and University of Utah Health-affiliated primary care and specialty clinics. PARTICIPANTS: Adults who screened positive for depressive symptoms (score≥10) on the Patient Health Questionnaire (PHQ-9) at an ambulatory visit between 1 January 2021 and 31 January 2022. A total of 17 651 patients were included in the study. OUTCOME MEASURES: Follow-up for positive depression screens was defined as a new antidepressant prescription or completed mental health visit. Variables associated with follow-up included patient demographic data, anthropometric measures, geographical classification, primary language, comorbidities and socioeconomic factors as well as provider demographics, level of training and clinic type. RESULTS: 5396 patients (30.6%) did not receive follow-up care for a positive PHQ-9 screen. Factors associated with lower rates of follow-up included male patients (gender; p=0.013), older patients (age group; p=0.016), non-White patients (ethnicity; p<0.0001), non-English (primary language; p<0.0001), lack of insurance (p<0.0001), older providers (p=0.027), male providers (p=0.0037) and attending-level providers (p<0.0001). CONCLUSIONS: Significant discrepancies in follow-up for positive depression screens in the ambulatory setting exist, particularly among racial/ethnic minority groups and patients who are non-native English speakers. Older providers and attending-level providers were less likely to facilitate follow-up for positive depression screens in their clinics.

  PublisherOA PDFDOI

• MON-343 Thyroid Nodule Evaluation Resulting in a Diagnosis of Medullary Thyroid Cancer and Papillary Thyroid Carcinoma Collision Tumor: A Case Report

  Journal of the Endocrine Society · 2025-10-01

  articleOpen accessSenior author

  Abstract Disclosure: R. Heinrich: None. K. Kaput: None. Background: This case provides valuable teaching points by describing the extremely rare (&amp;lt;1% of all thyroid tumors) presentation of a collision tumor consisting of two histologically distinct forms of thyroid cancer, medullary thyroid cancer and papillary thyroid carcinoma. Preoperative imaging often fails to identify two morphologically different nodules and fine needle aspiration of the nodule often only identifies one type of cancer, as occurred in this case. With each tumor typically having a different stage and prognosis, management often requires consideration of each tumor individually. Case Description: A 37 year old female presenting with a thyroid nodule located in the isthmus, with associated lymphadenopathy, was subsequently found to have a collision tumor consisting of papillary thyroid carcinoma and metastatic medullary thyroid cancer. The patient was initially found to have a thyroid nodule at the age of 22. At the age of 37, a neck ultrasound revealed a thyroid nodule located in the isthmus measuring 17 mm described as solid, hypoechoic with irregular margins. This was associated with an abnormal appearing right lateral neck (level 3) lymph node which notably had an abnormal short-to-long axis ratio and central calcification. Ultrasound-guided fine needle aspiration of the isthmus nodule revealed papillary thyroid carcinoma while the lymph node aspirate was nondiagnostic and negative for thyroglobulin wash. Repeat biopsy of the level three lymph node showed findings consistent with malignancy, favoring medullary thyroid cancer, though there were insufficient cells for diagnosis. Calcitonin and CEA were elevated at 219 pg/mL (reference 0-5 pg/mL) and 4.8 ng/mL (ULN 4.7 ng/mL) respectively. The patient underwent total thyroidectomy, central neck dissection and right lateral neck dissection. Surgical pathology revealed papillary thyroid carcinoma (15 mm, classic subtype) as well as a focus of medullary thyroid cancer (9 mm), both located in the right thyroid lobe and isthmus with disruption of the capsule. Four out of nine lymph nodes in the right central neck, five out of nine in the right lateral neck and one out of fifteen in the left lateral neck were positive for medullary thyroid cancer. The medullary thyroid cancer was staged as PT1aPN1b and the papillary thyroid carcinoma was staged as P1Tb PN0a. The patient had no known family history of multiple endocrine neoplasia syndrome or medullary thyroid cancer. Conclusion: Thyroid collision tumors are often undiagnosed on neck ultrasound and fine needle aspiration and thus the diagnosis may not become apparent until pathology from a surgical resection of a seemingly single thyroid nodule confirms the presence of two distinct tumors. This case provides an example of how collision tumors may not be detected by standard thyroid nodule evaluations but can drastically change how a thyroid nodule is eventually managed. Presentation: Monday, July 14, 2025

  PublisherOA PDFDOI

• 790 Bridging the gap: Improving family history documentation of diabetes in adults with cystic fibrosis

  Journal of Cystic Fibrosis · 2025-10-01 · 1 citations

  article1st authorCorresponding
  PublisherDOI

• Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass index

  Journal of Cystic Fibrosis · 2025-10-18 · 3 citations

  article
  PublisherDOI

• Isolated hyperphosphatasemia in adults with cystic fibrosis – a case series

  Journal of Cystic Fibrosis · 2025-07-05

  article
  PublisherDOI

• Metformin Blunts Bed Rest-induced Skeletal Muscle Ceramide Accumulation in Older Adults

  Physiology · 2024-05-01

  article

  Skeletal muscle insulin resistance is an undesirable outcome during periods of physical inactivity in older adults, which can lead to a variety of metabolic diseases. Insulin sensitive tissue (e.g., liver, and skeletal muscle) derived ceramides are well known to promote insulin resistance. Evidence suggests that metformin can regulate tissue ceramide accumulation. Therefore, we hypothesized that metformin treatment during a short-term period of bed rest in male and female older adults would reduce skeletal muscle ceramide accumulation and prevent insulin resistance. Our study design consisted of older adults (66 ± 4.5 y/o placebo, n=10; 71.7 ± 5.1 y/o metformin, n=10) who were subjected to 5 days of bed rest. Participants were randomly assigned to placebo or metformin treatment groups. Drug or placebo treatments started two weeks prior to bed rest and continued throughout the 5 days of bed rest. Prior to and after bed rest, participants underwent a euglycemic-hyperinsulinemic clamp. Muscle biopsies (from the vastus lateralis) were taken prior to and after each clamp both before and after bed rest. We found that insulin-stimulated muscle ceramides were increased after bed rest but were blunted in older adults who took metformin. In addition, muscle insulin resistance correlated with the increase in ceramides. We conclude that metformin was effective to reduce ceramide accumulation in muscle during a period of bed rest in older adults. R21AG064576 awarded to M.J.D. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

  PublisherDOI

Frequent coauthors

• Alec I. McKenzie

  University of Utah

  3 shared

• Matthew T. Rondina

  University of Utah

  2 shared

• Paul T. Reidy

  2 shared

• Lloyd Petty

  University of Florida

  2 shared

• Micah J. Drummond

  University of Utah

  2 shared

• Ziad S. Mahmassani

  University of Utah

  2 shared

• Jonathan J. Petrocelli

  University of Utah

  2 shared

• Matthew Wahl

  University of Utah

  2 shared